Archives of cardiovascular diseases
-
Arch Cardiovasc Dis · Nov 2012
Meta Analysis Comparative StudyZotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
The zotarolimus-eluting stent (ZES) is a new drug-eluting stent that delivers zotarolimus, a synthetic analogue of sirolimus, through a biocompatible phosphorylcholine polymer coating. ZES has shown promising results compared with bare-metal stents, but its safety and efficacy against sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents is yet to be established. ⋯ ZES is not superior to PES and is inferior to SES in terms of angiographic outcomes and clinically driven revascularization.